GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the research of a new approach to treating metastatic cancer. Under this grant, valued at over $300,000, GenVec will investigate the hypothesis that the delivery of a specific gene will stimulate an antitumor response that could control cancer metastases.
"Funding from this grant provides GenVec with an opportunity to expand our cancer program and explore a novel approach to cancer treatment," said Dr. Douglas Brough, GenVec's Executive Director, Head of Research. "The work expected to be conducted under this grant will explore new ways to control metastases, addressing a severely unmet medical need."
How different types of bread impact cancer risk